Advertisement

Tumor Biology

, Volume 37, Issue 9, pp 11883–11891 | Cite as

Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation

  • Guoqing Cai
  • Xiangdong Ma
  • Biliang Chen
  • Yanhong Huang
  • Shujuan Liu
  • Hong Yang
  • Wei Zou
Original Article

Abstract

Paclitaxel resistance becomes common in patients with aggressive ovarian cancer and results in recurrence after conventional therapy. Galectin-3 is a multifunctional lectin associated with cell migration, cell proliferation, cell adhesion, and cell-cell interaction in tumor cells. Whether circulating galectin-3 is involved in paclitaxel resistance in ovarian cancer remains unknown. The current study investigated the effect of galectin-3 on toll-like receptor 4 (TLR4) signaling and thus paclitaxel resistance. With blood and cancer tissue samples obtained from 102 patients, we identified associations between serum galectin-3 level or TLR4 expression and paclitaxel resistance phenotype. In vitro, treatment with exogenous galectin-3 restored cell survival and migration of SKOV-3 and ES-2 cells was decreased by galectin-3 silencing and paclitaxel treatment. Furthermore, exogenous galectin-3 boosted expression of TLR4, MyD88, and p-p65, as well as interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) release induced by paclitaxel. Moreover, galectin-3 inhibited the interaction between TLR4 and caveolin-1 (Cav-1) in SKOV-3 and ES-2 cells. In addition, overexpression of Cav-1 dampened the expression of MyD88 and p-p65 stimulated by galectin-3 and enhanced apoptosis in SKOV-3 cells under paclitaxel exposure. In summary, our study elucidated that exogenous galectin-3 might induce paclitaxel resistance through TLR4 signaling activation by inhibiting TLR4-Cav-1 interaction, revealing a novel insight into paclitaxel resistance induction.

Keywords

Galectin-3 Ovarian cancer Paclitaxel resistance Toll-like receptor 4 Caveolin-1 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81101959 and 81101958).

Compliance with ethical standards

This study was reviewed by the Ethics Committee of Xijing Hospital, the Fourth Military Medical University, and was performed in accordance with the Helsinki Declaration. Written informed consent was obtained from the patients enrolled in our study.

Conflicts of interest

None

References

  1. 1.
    Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97:2631–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27:161–74.PubMedGoogle Scholar
  3. 3.
    Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88.CrossRefPubMedGoogle Scholar
  4. 4.
    Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. In vitro fertilization is associated with an increased risk of borderline ovarian tumours. Gynecol Oncol. 2013;129:372–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W, et al. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy. J Exp Clin Cancer Res. 2013;32:25.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Matsuo K, Eno ML, Im DD, Rosenshein NB, Sood AK. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol. 2010;116:61–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Salani R, Kurman RJ, Giuntoli 2nd R, Gardner G, Bristow R, Wang TL, et al. Assessment of tp53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18:487–91.CrossRefPubMedGoogle Scholar
  8. 8.
    Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol. 2015;141:381–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006;66:3859–68.CrossRefPubMedGoogle Scholar
  10. 10.
    d’Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O’Crowley J, et al. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS One. 2014;9, e100816.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene. 2009;28:4353–63.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Song L, Tang JW, Owusu L, Sun MZ, Wu J, Zhang J. Galectin-3 in cancer. Clin Chim Acta. 2014;431:185–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Newlaczyl AU, Yu LG. Galectin-3—a jack-of-all-trades in cancer. Cancer Lett. 2011;313:123–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Yilmaz H, Celik HT, Ozdemir O, Kalkan D, Namuslu M, Abusoglu S, et al. Serum galectin-3 levels in women with PCOS. J Endocrinol Invest. 2014;37:181–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q, et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res. 2011;17:7035–46.CrossRefPubMedGoogle Scholar
  16. 16.
    Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Eliaz I. The role of galectin-3 as a marker of cancer and inflammation in a stage IV ovarian cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol. 2013;6:343–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Burguillos MA, Svensson M, Schulte T, Boza-Serrano A, Garcia-Quintanilla A, Kavanagh E, et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep 2015.Google Scholar
  19. 19.
    Arad U, Madar-Balakirski N, Angel-Korman A, Amir S, Tzadok S, Segal O, et al. Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts. Cytokine. 2015;73:30–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang AC, Ma YB, Wu FX, Ma ZF, Liu NF, Gao R, et al. TLR4 induces tumor growth and inhibits paclitaxel activity in MyD88-positive human ovarian carcinoma. Oncol Lett. 2014;7:871–7.PubMedGoogle Scholar
  21. 21.
    Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159:1635–43.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang XM, Kim HP, Nakahira K, Ryter SW, Choi AM. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J Immunol. 2009;182:3809–18.CrossRefPubMedGoogle Scholar
  23. 23.
    Harazono Y, Kho DH, Balan V, Nakajima K, Hogan V, Raz A. Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and p-glycoprotein signaling. Oncotarget. 2015;6:19592–604.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zhang H, Luo M, Liang X, Wang D, Gu X, Duan C, et al. Galectin-3 as a marker and potential therapeutic target in breast cancer. PLoS One. 2014;9, e103482.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, et al. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer. Gynecol Oncol. 2014;135:573–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Hossein G, Keshavarz M, Ahmadi S, Naderi N. Synergistic effects of pectasol-c modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 2013;14:7561–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Rajput S, Volk-Draper LD, Ran S. TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther. 2013;12:1676–87.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Volk-Draper L, Hall K, Griggs C, Rajput S, Kohio P, DeNardo D, et al. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014;74:5421–34.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Schlegel A, Pestell RG, Lisanti MP. Caveolins in cholesterol trafficking and signal transduction: implications for human disease. Front Biosci. 2000;5:D929–937.CrossRefPubMedGoogle Scholar
  30. 30.
    Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell. 2001;106:403–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Quann K, Gonzales DM, Mercier I, Wang C, Sotgia F, Pestell RG, et al. Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide. Cell Cycle. 2013;12:1510–20.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Wang XM, Kim HP, Song R, Choi AM. Caveolin-1 confers antiinflammatory effects in murine macrophages via the MKK3/p38 MAPK pathway. Am J Respir Cell Mol Biol. 2006;34:434–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Garrean S, Gao XP, Brovkovych V, Shimizu J, Zhao YY, Vogel SM, et al. Caveolin-1 regulates NF-kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide. J Immunol. 2006;177:4853–60.CrossRefPubMedGoogle Scholar
  34. 34.
    Jiao H, Zhang Y, Yan Z, Wang ZG, Liu G, Minshall RD, et al. Caveolin-1 Tyr14 phosphorylation induces interaction with TLR4 in endothelial cells and mediates MyD88-dependent signaling and sepsis-induced lung inflammation. J Immunol. 2013;191:6191–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Guoqing Cai
    • 1
  • Xiangdong Ma
    • 1
  • Biliang Chen
    • 1
  • Yanhong Huang
    • 1
  • Shujuan Liu
    • 1
  • Hong Yang
    • 1
  • Wei Zou
    • 1
  1. 1.Department of Obstetrics and Gynecology, Xijing Hospitalthe Fourth Military Medical UniversityXi’anPeople’s Republic of China

Personalised recommendations